Search the web
Welcome, Guest
[Sign Out, My Account]
Morningstar_Inc.

Wednesday, January 18 2017 8:56am ET - U.S. Markets open in 34 minutes.
Industry Center - Drugs - Generic
Industry Center > Drugs - Generic
More On This Industry
Summary
·News
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Biotechnology
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Manufacturers - Other
· Drug Related Products
Top Industries
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Diversified Utilities
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
·Tobacco Products, Other
Complete Industry List...
Morningstar Inc.
In-depth Company Dossier Reports on over 7,500 publicly traded U.S. companies. Click here for your free report.
  
Industry Market Summary
Drugs - Generic
Composite Value: 1061.8
Today's Change: -0.03%
S&P 500: -0.30%
chart for
[Drugs - Generic (^YHOh785)]
Drugs - Generic News
Neurocrine Announces Completion of Phase II Clinical Study of VMAT2 Inhibitor INGREZZA™ (valbenazine) in Adults with Tourette Syndrome
Tue 4:01 pm ET (PR Newswire)
While the study showed a significant improvement in overall symptoms of Tourette syndrome as evidenced by the Clinical Global Impression of Change (p=0.015), the pre-specified primary endpoint, the change-from-baseline in the Yale Global Tic Severity Scale (YGTSS) at Week 8 was not met (p=0.18). Adverse events were dose dependent and consistent with earlier clinical studies. "Overall we were very pleased with the conduct of the study, including the investigators' administration of the Yale Global Tic Severity Scale as well as the safety profile of INGREZZA in adults with Tourette syndrome," said Chris O'Brien, Chief Medical Officer of Neurocrine.
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm - ()
AGN Falls Despite Positive Trial Results - (at Investopedia)
More News on Drugs - Generic: Latest News,
Industry Top Performers
Intraday Price Performance% ChangeMarket Cap
More Top Intraday Price Performers...
Market Capitalization% ChangeMarket Cap
SUN PHARMACEUTICAL INDUSTRIES [SUNPHARMA.BO] +0.79% $1870.3 B
ALLERGAN PLC [AGNN.MX] -0.72% $1750.1 B
SUN PHARMACEUTICAL INR1(DEMAT) [SUNPHARMA.NS] +0.52% $1546.6 B
LUPIN LTD. [LUPIN.BO] +0.31% $710.7 B
TEVA PHARMACEUTICAL INDUSTRIES [TEVAN.MX] -3.45% $705.2 B
More Top Companies by Market Cap...
More Top Performers: by Valuation, by Growth, by Financial Strength
Industry Calendar
Upcoming Events
Date Co Event
01/26/17 ORX.ST Orexo AB Q4 2016 Earnings Release
02/04/17 DRREDDY.NS Dr.Reddy's Laboratories Ltd Q3 2017 Earnings Release
02/07/17 MNK Mallinckrodt Plc Earnings Call (Q1 2017)
More Upcoming Events...
Recent Events
Date Co Event
01/09/17 EGRX Eagle Pharmaceuticals, Inc. downgraded by Mizuho
01/05/17 EVOK Evoke Pharma, Inc. upgraded by Rodman & Renshaw
01/05/17 MYL Mylan N.V. downgraded by Citigroup
More Recent Events...
  
Locate Industry by Company
Enter Symbol:
Industry Statistics
Market Capitalization:809B
Price / Earnings:NM
Price / Book:-4.3
Net Profit Margin (mrq):-4.8%
Price To Free Cash Flow (mrq):-7.3
Return on Equity:0.0%
Total Debt / Equity:49.3
Dividend Yield:2.1%
View Industry Browser
Community Spotlight
Most Active Boards
Board Popularity
SRLS
GNVC
WPI
Unusually Active Boards
Board Variance
SRLS
GNVC
WPI

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Drugs - Generic Headlines
More Finance RSS Feeds


Copyright © 2017 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2017 Morningstar, Inc. All Rights Reserved. Company information © 2017 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?